GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ipsen SA (XTER:I7G) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Ipsen (XTER:I7G) Future 3-5Y EPS without NRI Growth Rate : 5.95 (As of Sep. 25, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Ipsen Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Ipsen's Future 3-5Y EPS without NRI Growth Rate is 5.95.

Competitive Comparison of Ipsen's Future 3-5Y EPS without NRI Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Ipsen's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ipsen's Future 3-5Y EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ipsen's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Ipsen's Future 3-5Y EPS without NRI Growth Rate falls into.


Ipsen  (XTER:I7G) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Ipsen Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Ipsen's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Ipsen Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ipsen SA (XTER:I7G) » Definitions » Future 3-5Y EPS without NRI Growth Rate
Comparable Companies
XPAR:VETO XPAR:BOI XPAR:EAPI XPAR:AB XPAR:MLCOT XPAR:ALRPD XTER:MRK ZTS NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD XTAE:TEVA XSWX:SDZ NBIX NSE:DIVISLAB BOM:532321 VTRS BOM:500124 NSE:TORNTPHARM
Traded in Other Exchanges
IPSEY:USA IPSEF:USA IPNp:UK 0MH6:UK IPN:France I7G:Germany IPN:Austria
Address
65 Quai Georges Gorse, Billancourt Cedex, Boulogne, FRA, 92100
Website
https://www.ipsen.com
Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was founded in 1929 as a consumer healthcare company focused on prescription-based products for digestive disorders and neurological disorders. Over the past nearly 100 years, Ipsen has shifted its focus to specialty care, which comprises the vast majority of its total revenue. In February 2022, Ipsen announced the divestment of its consumer healthcare business, which accounted for 8% of 2021 revenue. Ipsen has a large global footprint and sells more than 25 drugs in 115 countries.

Ipsen Headlines

No Headlines